Drugs / rapcabtagene autoleucel
Trials 11
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT07443137 | Jul 2026 → Aug 2028 expected | large B-cell lymphoma | Stanford University | Not yet recruiting | No outcome recorded |
| Phase 1/26 trials | ||||||
| Phase 1/2 | NCT07048197 | Jun 2025 → Nov 2028 expected | Sjogren syndrome, rheumatoid arthritis | Novartis Pharmaceuticals | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT06704269 | Apr 2025 → Oct 2029 expected | generalized myasthenia gravis | Novartis Pharmaceuticals | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT06617793 | Feb 2025 → Aug 2030 expected | multiple sclerosis | Novartis Pharmaceuticals | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT06675864 | Dec 2024 → Jun 2030 expected | multiple sclerosis | Novartis Pharmaceuticals | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT05798117 | Feb 2023 → Sep 2026 | lupus nephritis, systemic lupus erythematosus | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 1/2 | NCT03960840 | Jun 2019 → Jun 2027 expected | chronic lymphocytic leukemia/small lymphocytic lymphoma, diffuse large B-cell lymphoma, large B-cell lymphoma | Novartis Pharmaceuticals | Active not recruiting | No outcome recorded |
| Phase 24 trials | ||||||
| Phase 2 | NCT06868290 | Mar 2025 → Jun 2029 expected | anti-neutrophil cytoplasmic antibody-associated vasculitis | Novartis Pharmaceuticals | Active not recruiting | No outcome recorded |
| Phase 2 | NCT06665256 | Dec 2024 → Mar 2029 expected | idiopathic inflammatory myopathy | Novartis Pharmaceuticals | Active not recruiting | No outcome recorded |
| Phase 2 | NCT06655896 | Oct 2024 → Nov 2028 expected | diffuse cutaneous systemic sclerosis | Novartis Pharmaceuticals | Active not recruiting | No outcome recorded |
| Phase 2 | NCT06581198 | Sep 2024 → Feb 2028 expected | lupus nephritis, systemic lupus erythematosus | Novartis Pharmaceuticals | Active not recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 4
| Date | Issuer | Release |
|---|---|---|
| 2025-10-25 | Novartis Pharmaceuticals | Results Novartis showcases significant immunology advancements in ACR congress with new data in complex autoimmune diseases novartis.com ↗
Biomarker data from an open-label, Phase 1/2 Study for YTB323 (Rapcabtagene Autoleucel, a rapidly manufactured CD19 CAR-T therapy) suggest reset of the B Cell compartment in severe refractory SLE |
| 2022-11-22 | Novartis Pharmaceuticals | Results Novartis highlights scientific advances with Kisqali, iptacopan, Scemblix and YTB323 data at SABCS and ASH novartis.com ↗
YTB323 (rapcabtagene autoleucel) demonstrates durable efficacy and a manageable safety profile in patients with relapsed/refractory diffuse large B-cell lymphoma (r/r DLBCL): Phase I study update |
| 2021-12-13 | Novartis Pharmaceuticals | Results Novartis announces T-Charge™, next-generation CAR-T platform with first-in-human data at ASH 2021 novartis.com ↗
Initial efficacy results include 73% complete response rate at month three with dose level two in the YTB323 study in DLBCL and 100% best overall response in the PHE885 study in multiple myeloma |
| 2021-12-02 | Novartis Pharmaceuticals | Results Novartis R&D day spotlights attractive growth profile, underpinned by strong in-market brands, 20 potential high value pipeline assets, and technology platforms novartis.com ↗
In first-in-human trials to be presented at ASH 2021, lead candidates YTB323 and PHE885 showed 75% Complete Response in Diffuse Large B-Cell Lymphoma (DLBCL) at three months and 100% Best Overall Response (BOR) in multiple myeloma, respectively. |
All press releases naming this drug 4 releases
| Date | Issuer | Release |
|---|---|---|
| 2025-10-25 | Novartis Pharmaceuticals | Novartis showcases significant immunology advancements in ACR congress with new data in complex autoimmune diseases novartis.com ↗ |
| 2022-11-22 | Novartis Pharmaceuticals | Novartis highlights scientific advances with Kisqali, iptacopan, Scemblix and YTB323 data at SABCS and ASH novartis.com ↗ |
| 2021-12-13 | Novartis Pharmaceuticals | Novartis announces T-Charge™, next-generation CAR-T platform with first-in-human data at ASH 2021 novartis.com ↗ |
| 2021-12-02 | Novartis Pharmaceuticals | Novartis R&D day spotlights attractive growth profile, underpinned by strong in-market brands, 20 potential high value pipeline assets, and technology platforms novartis.com ↗ |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 12 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Rapcabtagene autoleucel | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03960840 ↗ |
| Known as | Rapcabtagen autoleucel | ChEMBL registry synonym — accepted as the source's own label CHEMBL5095147 ↗ |
| Known as | YTB323 | “This is a phase I/II study to evaluate the feasibility, safety and preliminary antitumor efficacy of rapcabtagene autoleucel (also known as YTB323).” NCT03960840 ↗6“Single infusion of rapcabtagene autoleucel (YTB323)” NCT06868290 ↗ “Biological: rapcabtagene autoleucel (YTB323)” NCT06675864 ↗ “rapcabtagene autoleucel (YTB323)” NCT06617793 ↗ “Rapcabtagene autoleucel (YTB323)” NCT07443137 ↗ |
| Modality | Cell therapy | “CAR-T cell suspension” NCT06617793 ↗ |
| Route | Intravenous | “CAR-T cell suspension for intravenous infusion” NCT06617793 ↗ |
| Target | CD19 | “Autologous CD19-directed chimeric antigen receptor (CAR) T-cell therapy” NCT07443137 ↗ |